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Purpose: Dendritic cell (DC) vaccination for melanoma was introduced because 
melanoma carries distinct tumor-associated antigens. The purpose of this study 
was to investigate the efficacy and safety of DC vaccination for melanoma in Ko-
rea. Materials and Methods: Five patients with stage IV and one with stage II 
were enrolled. Autologous monocyte-derived DCs (MoDCs) were cultured and 
pulsed with tumor-lysate, keyhole limpet hemocyanin, and cytokine cocktail for 
mature antigen-loaded DC. DC vaccination was repeated four times at 2-week in-
tervals and 2-4×107 DC were injected each time. Results: Reduced tumor volume 
was observed by PET-CT in three patients after DC vaccination. Delayed type hy-
persensitivity responses against tumor antigen were induced in five patients. Tumor 
antigen-specific IFN-γ-producing peripheral blood mononuclear cells were detected 
with enzyme-linked immunosorbent spot in two patients. However, the overall 
clinical outcome showed disease progression in all patients. Conclusion: In this 
study, DC vaccination using tumor antigen-loaded, mature MoDCs led to tumor re-
gression in individual melanoma patients. Further standardization of DC vaccination 
protocol is required to determine which parameters lead to better anti-tumor respons-
es and clinical outcomes.
Key Words:  Dendritic cell, immunotherapy, malignant melanoma
INTRODUCTION
Malignant melanoma is less common than non-melanoma skin cancer, but its inci-
dence has increased substantially over the past two decades.1 However, it accounts 
for the majority of mortality associated with skin cancer.2 Even though primary tu-
mor excision is the choice of treatment, melanomas are occasionally beyond surgi-
cal margins when diagnosed, and are usually resistant to chemotherapy and radio-Dendritic Cells Immunotherapy of Malignant Melanoma
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ma, ECOG performance status 0 or 1, sufficient tumor tis-
sue (more than 2 gm) for tumor antigen, available mono-
cyte for DC culture, and lack of benefit from conventional 
cancer treatments such as well-established chemotherapy, 
radiotherapy and surgical operations. The exclusion criteria 
stated that patients could not have any other severe medical 
conditions or psychiatric diseases that would contraindicate 
study participation. Previous treatment with chemotherapy, 
cytokines, or active immunotherapy including systemic corti-
costeroids within three months of the study was not allowed. 
The clinical study was conducted in accordance with the 
Declaration of Helsinki. Written informed consent was ob-
tained from the patients before they began the study. Pa-
tients were enrolled from May 2006 to March 2008 at the 
Yonsei Cell Therapy Center of Severance Hospital, Yonsei 
University Health System, Seoul, Korea. The study proto-
col was approved by the Institutional Review Board of 
Yonsei University Health System’s Clinical Trial Center 
and by the Korea Food & Drug Administration.
Preparation of monocyte-derived DC
For the preparation of monocyte-derived DC, we referred to 
the previous publication of our group.6 Peripheral blood 
mononuclear cells (PBMCs) were isolated from leukaphere-
therapy.3 Therefore many other therapeutic modalities are 
being investigated, and one of them is a dendritic cell (DC)-
based cancer vaccine. In 1996, the DC-based vaccine was 
first introduced to treat B-cell lymphoma.4 Further clinical 
trials of the DC vaccination have been performed for treat-
ment of melanoma, colorectal carcinoma, lung carcinoma, 
renal cancer, prostatic cancer, and multiple myeloma.5 
However, the DC vaccination for malignant melanoma is 
still in its early phases in South Korea. Here, we report the 
results of a clinical trial with six Korean patients with ad-
vanced malignant melanoma who were treated with vacci-
nation with mature, monocyte-derived DCs.
MATERIALS AND METHODS
Study design and eligibility criteria 
The study was designed as an investigator-initiated clinical 
study to evaluate the safety and effectiveness of autologous 
monocyte-derived DC vaccination for malignant melano-
ma. Five patients had stage IV melanoma and one patient 
had stage II melanoma according to the AJCC staging sys-
tem (Fig. 1). The eligibility criteria stated that patients were 
required to have histologically proven metastatic melano-
Fig. 1. Patients had multiple cutaneous metastases and recurrent melanoma in the tonsil. Because the whole tumor-lysate was used for 
antigen pulsing, it was important to have sufficient tumor volume.   Dae Suk Kim, et al.
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ing a kinetic method at the Celltec Bio-research Center 
(Bucheon, Korea). Sterility tests were performed at our 
own facility by members of the Department of Laboratory 
Medicine. 
       
Vaccination protocol
Patients received subcutaneous injections of 2-4×107 cells of 
tumor-lysate-pulsed DC into the groin, axilla and neck at two 
week intervals. Each patient was assigned to receive four DC 
vaccinations. Complete response was defined as the disap-
pearance of all targeted lesions. Partial response (PR) was de-
fined as a decrease of at least 30% in the sum of the longest 
diameter (LD) of the target lesions, with the baseline sum LD 
as a reference. Progression of disease (PD) was defined as an 
increase of at least 20% in the sum of the LD sum value re-
corded at the start of treatment. Stable disease (SD) was de-
fined as neither sufficient shrinkage to qualify for PR nor suf-
ficient increase to qualify for PD, with the smallest sum LD 
as a reference.
Clinical outcome assessment
The patients were evaluated for toxicity and clinical response 
after undergoing four vaccinations. Clinical outcome was 
evaluated based on the analysis of whole body PET-CT im-
ages before and after the fourth vaccination.
Delayed type hypersensitivity response (DTH)
DTH was examined before and after each vaccination. Pa-
tients received intradermal injections of 100 uL of normal 
saline, tumor lysate 100 ug, KLH 50 ug and tumor antigen 
100 ug plus KLH 50 ug at different sites on the forearm. The 
concentration of tumor antigen was 100 µg/mL and of KLH 
was 50 µg/mL. Forty-eight hours later, DTH was scored pos-
itive if the areas of erythema and induration were greater 
than 5 mm. 
Flow cytometry analysis
To assure the characters of immature and mature DC, the 
surface molecules were identified using flow cytometry anal-
ysis. In brief, the cells were washed with 0.4% BSA/PBS 
and stained for 30 minutes at 4°C with monoclonal antibod-
ies conjugated to fluorochromes against CD1a, CD3, CD4, 
CD8, CD14, CD16, CD19, CD45, CD56, CD80, CD83, 
CD86, HLA-ABC and HLA-DR (all from Pharmingen). Af-
ter two washes with 0.4% BSA/PBS, flow cytometric anal-
ysis was performed by FACSCalibur (BD Biosciences, 
Franklin Lakes, NJ, USA). 
sis products using a commercially available apheresis system 
(COBE Spectra, Lakewood, CO, USA). In brief, the leuka-
pheresis product was loaded via the inlet pump into the con-
stantly rotating (2,400 rpm) elutriation chamber. The automa-
tion mode produced five elutriation fractions, each specified 
by centrifuge speed, loading or elutriation buffer flow rate, 
and process volume. The final monocyte-rich fraction (Frac-
tion 5) was collected from the chamber into the final collec-
tion bag when the centrifuge was stopped. All procedures 
were conducted according to the manufacturer’s recommen-
dations, except that we used Hanks’ buffered salt solution 
(HBSS; Bio-Whittaker, East Rutherford, NJ, USA) as an elu-
triation buffer. Enriched monocytes were cultured on T75 
culture flasks (Greiner Bio-One GmbH, Monroe, NC, USA) 
in X-VIVO 15 (Bio-Whittaker), 20 µg/mL gentamicin, 2 mM 
glutamine, 5% heat-inactivated AB human plasma, 250 ng/
mL recombinant human (rHu) GM-CSF (Leucogen, Singa-
pore), and 20 ng/mL rHu IL-4 (Pharmingen, San Diego, CA, 
USA). Cultures were fed every other day by removing half of 
the supernatant and adding fresh medium with full doses of 
cytokines. On day 6, immature DC (iDC) were generated and 
harvested for tumor antigen loading. Several other papers 
give more detailed information on monocyte enrichment and 
DC identification using surface markers.6,7
Preparation of tumor lysate-pulsed mature DC for 
vaccination
Tumor lysate was prepared using freezing/thawing tech-
niques previously described by Nakai, et al.8 In brief, tumor 
specimens were immediately placed in phosphate-buffered 
saline (PBS). Subsequently, adjacent normal tissue was re-
moved using a scalpel, and tumor cells were dispersed to 
create a single-cell suspension. The cells were lysed by four 
to five freeze cycles (on liquid nitrogen) and thaw cycles 
(room temperature). The larger particles were removed by 
centrifugation (10 min, 400 g). The supernatants were 
passed through a 0.22-µm filter, protein concentration was 
determined and aliquots were stored at -80°C until use. To 
induce maturation, immature DCs were cultured for 48 
hours in medium containing 100 µg/mL of autologous tu-
mor lysate, keyhole limpet hemocyanin (KLH), cytokine 
cocktail (20 ng/mL TNF-α, 500 U/mL IL-1β, 500 U/mL 
IL-6 (all from Pharmingen), and 10-7 mol/L PGE2 (Sigma 
Chemical Co., St. Louis, MO, USA). After 48 hours, the 
cells were harvested and analyzed. Before injection, we 
performed endotoxin and mycoplasma tests with superna-
tants. Endotoxin and mycoplasma tests were performed us-Dendritic Cells Immunotherapy of Malignant Melanoma
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neck skin, small intestines and tonsils. All patients had re-
ceived surgery, two patients had received prior chemothera-
py, and one patient received prior radiofrequency ablation 
for metastatic liver disease. Although patient 2 had stage II 
disease, recurrent tumors in the oral cavity were neither op-
erable nor responsive to chemotherapy.  
Therapeutic-DC characteristics 
We performed leukapheresis on six melanoma patients and 
obtained DCs of acceptable quality and quantity for vaccina-
tion (Table 2). The average recovery of mononuclear cells 
and monocytes after leukapheresis were 7.9±5.5×109, 
1.9±1.0×109 respectively. After elutriation, average mono-
cyte recovery and monocyte fraction purity were 1.2±1.0 
×109, 49.9±30.2%. For each vaccination, iDCs were generat-
ed from a frozen aliquot of enriched monocytes in the pres-
ence of rh GM-CSF, rh IL-4 and 5% heat-inactivated AB 
human plasma (Fig. 2A). Since autologous plasma from 
melanoma patients can have a negative influence, we used 
heat-inactivated AB fresh frozen plasma stored for transfu-
sion, making it not a single lot. We had to use AB plasma 
from different donors for each injection. On day 6, iDCs ob-
tained were CD80-, CD83-, CD86low+, HLA-DR+ (Fig. 2B). 
They were co-cultured for 48 hours with autologous tumor 
lysate, KLH, TNF-α, IL-1β, IL-6 and PGE2. CD80+, CD83+, 
CD86high+, HLA-DR+ mature DC (mDC) were obtained 
(Fig. 2C). There was no endotoxin, mycoplasma, or bacteri-
al contamination in the media of the cultured DCs.
Safety
Overall, the vaccine was well-tolerated. Only two patients 
(patient 2, 3) reported minor flu-like symptoms (grade I). 
Interferon-γ enzyme-linked immunosorbent spot 
(IFN-γ ELISPOT) assay 
PBMC (5×105 cells/well) were added to plates pre-coated 
with 5 μg/mL of a primary anti-IFN-γ monoclonal antibody 
(BD Biosiences) in the presence of 10 μg/mL tumor lysate 
as an antigen and incubated for 48 hours. The negative con-
trols for the assay were unstimulated PBMCs. A positive 
response was arbitrarily defined as at least a two-fold in-
crease in antigen-specific IFN-γ ELISPOT and at least 10 
spots/5×105 PBMC at any time point post-DC vaccination.
Enzyme-linked immunosorbent assay (ELISA) 
To measure IL-10, IL-12p70, IFN-γ and TGF-β in the pe-
ripheral blood, ELISA was performed before first vaccina-
tion and after the fourth vaccination. Quantities of IL-10, 
IL-12p70, IFN-γ and TGF-β were measured by using Op-
tEIA (BD OptEIA human ELISA kit; BD Bioscience) as 
described by the manufacturer. 
RESULTS
 
Patients 
This clinical trial was conducted on six patients with ad-
vanced malignant melanoma. Table 1 shows the patient char-
acteristics at the time of study entry. Their mean age was 58 
years (range: 39-81 years). There were four males and two 
females. Five patients had stage IV disease and one patient 
had stage II disease. The site of the primary tumor varied. 
Three patients had primary acral lentiginous melanoma, 
which is the most common type of malignant melanoma in 
Asians. The others had primary tumors on the posterior 
Table 1. Characteristics of Enrolled Patients
Patient 
No. Sex/Age Past history Site of primary tumor Previous treatment Stage Site of metastasis
1   F/49  - Skin (posterior neck) Surgery,   
  chemotherapy IV Lymph nodes, skin, lung, bone, 
  liver
2*   F/81 Diabetes mellitus, 
  hypertension Skin (Rt. heel) Surgery IV Lymph nodes, skin, brain
3
† M/39 - Skin (Rt. sole) Surgery IV Lymph nodes, lung
4 M/50 - Small bowel Surgery, RFA IV Liver, bladder
5 M/71 - Skin (Lt. 5th toe) Surgery IV Lymph nodes, skin, lung, brain,  
  bone, adrenal gland, peritoneum
6 M/60 - Tonsil Surgery,  
chemotherapy II
DC, dendritic cell.
*Patient 2 exhibited multiple lymph nodes and skin metastases at initial evaluation, but brain metastasis was found 1 month after the 4th DC vaccination. 
†Patient 3 exhibited multiple lymph nodes metastases and X-ray and CT findings of diffuse interstitial lung disease (DILD) at initial evaluation, but lung 
biopsy revealed pulmonary hematolymphangitic metastasis during the 2nd DC vaccination.Dae Suk Kim, et al.
Yonsei Med J   http://www.eymj.org   Volume 52   Number 6   November 2011 994
lymph nodes at the left supraclavicular fossa, bilateral retro-
peritoneal area, right inguinal area and right axilla after the 
fourth vaccination in patient 3 (Fig. 3). Patient 4 showed im-
provement in the extrahepatic lymph nodes inferior to liver. 
In case of patient 5, intensity on PET-CT decreased in the 
right upper paratracheal lymph nodes, right femur, L4 spine, 
left distal humerus and left inguinal lymph nodes. Due to 
rapid disease progression, post treatment PET-CT was not 
performed in patient 1. After three vaccinations, patient 6 
showed no difference in PET-CT. Tumor volume increased 
in patient 2. In spite of tumor volume reduction in patients 3, 
4 and 5, every patient experienced disease progression even-
However these symptoms did not lead to early withdrawal 
from the study. No clinical signs of autoimmune reactions 
about melanocytes, such as vitiligo and halo nevus, were 
detected. In all patients, blood tests revealed no treatment-
related hematologic, renal or hepatic toxicity. 
Clinical responses in vaccinated patients 
Of the six enrolled patients, two of them (patients 1, 6) with-
drew from the study due to rapidly progressive disease (Ta-
ble 2). In the cases of patients 3, 4 and 5, reduction of tumor 
volume was noted on the PET-CT (reviewed by Nuclear 
Medicine professor, J.D.L.). Improvement was found in the 
Table 2. Dendritic Cell Vaccines, Clinical and Immune Monitoring, and Response
Patient 
No.
No. of 
vaccines
Cell counts  
(×10
7 cells/vaccines) Site of vaccines
Tumor  
reduction in 
PET-CT
DTH* ELISPOT
† ELISA
‡ Side effect
§ Clinical  
outcomes
1 2 3.3±1.8 Axilla ND ND ND ND N/A N/A
2 4 2.2±0.2 Groin - + negative ND - PD
3 4 4.0±1.8 Axilla, groin + + positive + - PD
4 4 4.4±0.7 Groin + + ND + - PD
5 4 4.0±0.3 Groin, neck + + ND + - PD
6 3 3.7±0.4 Axilla, groin, neck - + ND ND N/A N/A
PET-CT, positron emission tomography-computed tomography; ND, not done; PD, progressive disease; N/A, not applicable; PBMCs, Peripheral blood 
mononuclear cells. Mean follow up: 4.6 months. 
*Delayed type hypersensitivity (DTH) was examined for antigen-specific immunity. 
†Enzyme-linked immunosorbent spot (ELISPOT) assay was performed for the detection of antigen-specific IFN-γ-producing PBMCs. 
‡Enzyme-linked immunosorbent assay (ELISA) was performed for the detection of IL-12, IL-10, IFN-γ, TGF-β. 
§Side effects included only mild flu-like symptoms and all patients tolerated treatment well. 
Fig. 2. The immunophenotypic profiles of enriched monocytes (A); immature DC on day 6 of culture with GM-CSF and IL-4 (B); and mature DC cultured after 
an additional 2 days with tumor lysate, KLH and cytokine cocktail (TNF-a, IL-1b, IL-6, and PGE2) (C). Each of the cells was stained with monoclonal antibodies 
specific to CD1a, CD14, CD45, CD80, CD83, CD86, HLA-ABC and HLA-DR. Mature DCs have a higher expression of HLA-DR, CD86, and CD80 than immature 
DCs. Only mature DCs express CD83. The data shown are from one representative experiment. DC, dendritic cell; KLH, keyhole limpet hemocyanin.
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rapid disease progression. Post-vaccination DTH test re-
vealed vaccination-induced tumor antigen-specific reactivi-
ty in the other five patients (Fig. 4). Since some patients quit 
the clinical trial or expired during the study, we lacked speci-
mens for the assays. Therefore, IFN-γ ELISPOT assay was 
performed only in patients 2 and 3 (Table 2). ELISPOT as-
say detected an increase in antigen-specific IFN-γ produc-
ing PBMCs in both of these patients (Fig. 5). In patient 3, 
antigen-specific IFN-γ producing PBMCs increased more 
tually. Patient 6 was lost during follow up. The other five pa-
tients expired within a year of their last vaccination. The 
mean survival period was 4.6 months for these five patients. 
Immune responses 
DTH was examined for antigen-specific immunity. DTH 
reactions were measured before and after each vaccination. 
None of the patients had positive pre-vaccination DTH re-
actions. Patient 1 was unable to receive the DTH test due to 
Fig. 3. Tumor volume reduction in PET-CT. In the case of patient 3, reduction of tumor volume was noted in PET-CT after the 4th vaccina-
tion. The lymph nodes at the Lt. supraclavicular fossa, bilateral retroperitoneal lymph node chain, Rt. inguinal area and upper part of right 
axillary lymph nodes were pointed out as sites of improvement. 
Fig. 4. Patient 3 showing positive reactions to the DTH test. DTH was examined before and then 2 weeks after the 4th vaccination. 
Patients received i.d. injections of 100 μL of normal saline, 100 μg tumor lysate, 50 μg KLH, 100 μg tumor lysate, plus 50 μg KLH, at separate 
sites on the forearm. Forty-eight hours later, DTH was scored positive if the areas of erythema and induration were greater than 5 mm. 
DTH, delayed type hypersensitivity; KLH, keyhole limpet hemocyanin.
July 21st, 2006 Nov 8th, 2006Dae Suk Kim, et al.
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sibility of utilizing DC vaccination as an adjuvant therapy. 
The patient in case 3 showed noticeable tumor volume 
reduction within just three months. The size of the lymph 
nodes at the left supraclavicular fossa, bilateral retroperito-
neal area, right inguinal area and right axilla was markedly 
reduced after the fourth vaccination according to the PET-
CT. Because patient 3 was in his thirties, good clinical re-
sponses were expected. He also had positive DTH response, 
increased antigen-specific IFN-γ producing PBMCs on the 
ELISPOT assay and increase in IFN-γ as well as TGF-β in 
the peripheral blood. However, the patient expired one month 
after the fourth vaccination. This outcome may have been 
partially related to TGF-β expressing T cells. A recent study 
indicates that the survival of DC-vaccinated malignant mel-
anoma patient is correlated with the reduction of TGF-β ex-
pressing T cells.9 Regulatory T cells (Tregs) are a subpopu-
lation of T cells that constitutively express high levels of 
CD25.10 Tumor antigen-specific Tregs are known to play an 
immune suppressive role to the antigen. Liyanage, et al.11 
showed that the prevalence of tumor antigen-specific Tregs 
is higher in patients with advanced tumor disease. A high 
number of tumor antigen-specific Tregs has also been shown 
to be related to reduced survival.12 In addition, Tregs are able 
to induce tolerogenic DC, thereby developing anergic and 
than five times after vaccination. Cytokine levels in periph-
eral blood were measured with ELISA for IL-4, IL-12, IFN-γ 
and TGF-β before and after the fourth vaccination (Table 3). 
Only patients 3, 4 and 5 had completed ELISA before and 
after vaccination. In patient 3, IL-12 increased after vacci-
nation. However, TGF-β also increased. In patients 4 and 5, 
IFN-γ and IL-12 increased after vaccination.  
DISCUSSION
   
Here, we performed DC vaccinations in six patients with 
malignant melanoma. In this study, DC vaccination using 
tumor-antigen loaded DCs led to tumor volume regression 
in three of the six patients, which was evaluated by PET-
CT. DTH responses were positive in five patients. IFN-γ pro-
ducing PBMCs were detected in two patients by ELISPOT 
assay. However, rapid disease progression was seen in al-
most all patients. Since none of the patient survived more 
than a year after the last vaccination, according to our re-
sults, we consider our DC immunotherapy method to be in-
sufficient as a single treatment modality for malignant mel-
anoma with distant metastasis. Nevertheless, positive DTH 
and tumor volume reduction on the PET-CT showed the pos-
Table 3. ELISA for Cytokine Detection
Patient No. IL-4 (pg/mL) IL-12 (pg/mL) IFN-γ (pg/mL) TGF-β (pg/mL)
3
   Before 0   8.9 0 499.2
After 0 18.4 0 818.1 
4
   Before  36.6 17.6  87.4  0
After  88.8 10.7 217.4   0
5
   Before  16.2 11.3  38.6  0
After  11.4 41.6  26.7  0
ELISA, enzyme-linked immunosorbent assay.
ELISA for the detection of IL-4, IL-12, IFN-γ, TGF-β was performed before the 1st vaccination and after the 4th vaccination.
Fig. 5. ELISPOT for the detection of Ag-specific IFN-γ producing PBMCs in patient 2, 3. Both patients showed positive results. ELISPOT, 
enzyme-linked immunosorbent spot.
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of immunoresistance by the tumor.21 As advanced disease 
impairs the host immune system and promotes tumor im-
mune evasion, DC vaccination would be more efficient if 
performed in less advanced disease. 
In this study, DC vaccination using tumor antigen loaded 
with mature, monocyte-derived DC led to tumor regression 
in individual melanoma patients. However, there was a huge 
discrepancy between the strong antigen-specific T cell re-
sponses ex vivo and the weak clinical responses. Despite 
this, positive DTH responses and tumor volume reduction 
on PET-CT showed the possibility of utilizing DC immu-
notherapy as an adjuvant therapy. As mentioned in the dis-
cussion, it would be much more effective if DC vaccines 
were used as an adjuvant therapy in less advanced melano-
ma patients after depleting Tregs. Further clinical trials 
should be conducted in patients with less advanced disease 
with the elimination of Tregs. In addition, standardized treat-
ment methods are lacking due to the high cost of clinical 
studies and the associated ethical issues. Hence, clinical 
studies of numerous patients of melanoma are needed from 
multiple institutions to determine the ideal parameters for 
DC immunotherapy in every aspect.
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